Identification
- Generic Name
- Setiptiline
- DrugBank Accession Number
- DB09304
- Background
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Setiptiline (DB09304)
- Weight
- Average: 261.368
Monoisotopic: 261.151749616 - Chemical Formula
- C19H19N
- Synonyms
- Setiptilina
- Setiptiline
- Setiptilinum
- External IDs
- MO-8282
- Org 8282
Pharmacology
- Indication
For the treatment of depression 4.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Setiptiline is a tertacyclic antidepressant 4. It acts to reduce the symptoms of major depressive disorder.
- Mechanism of action
Setiptiline is an antagonist at the α2 adrenergic receptor and at serotonin receptors 3,5. The antagonism of the α2 receptors likely relieves presynaptic inhibition of adrenergic neurotransmission, allowing for greater and longer sustained release of noradrenaline into the synapse. The antagonism of serotonin receptors may produce an upregulation of the receptors leading to an eventual increase in serotonergic signalling. The actual physiological mechanisms behind the antidepressant effect of setiptiline is unknown but the listed possibilities exist as likely explanations.
Target Actions Organism UAlpha-2 adrenergic receptors antagonistHumans USerotonin Receptors antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareIsocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Setiptiline. Levothyroxine The risk or severity of adverse effects can be increased when Levothyroxine is combined with Setiptiline. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Setiptiline. Methylene blue The risk or severity of adverse effects can be increased when Methylene blue is combined with Setiptiline. Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Setiptiline. Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Setiptiline. Nialamide The risk or severity of adverse effects can be increased when Nialamide is combined with Setiptiline. Pargyline The risk or severity of adverse effects can be increased when Pargyline is combined with Setiptiline. Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Setiptiline. Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Setiptiline. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Setiptiline maleate 9VOZ30EO2Y 85650-57-3 AVPIBVPBCWBXIU-BTJKTKAUSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Dibenzocycloheptenes
- Sub Class
- Not Available
- Direct Parent
- Dibenzocycloheptenes
- Alternative Parents
- Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Amine / Aromatic heteropolycyclic compound / Azacycle / Dibenzocycloheptene / Hydrocarbon derivative / Organic nitrogen compound / Organoheterocyclic compound / Organonitrogen compound / Organopnictogen compound / Tertiary aliphatic amine
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 7L38105Z6E
- CAS number
- 57262-94-9
- InChI Key
- GVPIXRLYKVFFMK-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H19N/c1-20-11-10-18-16-8-4-2-6-14(16)12-15-7-3-5-9-17(15)19(18)13-20/h2-9H,10-13H2,1H3
- IUPAC Name
- 4-methyl-4-azatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(19),2(7),8,10,12,15,17-heptaene
- SMILES
- CN1CCC2=C(C1)C1=CC=CC=C1CC1=CC=CC=C21
References
- General References
- Niho T, Ito C, Shibutani Y, Hashizume H, Yamaguchi K: [Pharmacological properties of MO-8282, a novel antidepressant]. Nihon Yakurigaku Zasshi. 1986 Oct;88(4):309-20. [Article]
- Przegalinski E, Baran L, Siwanowicz J, Rawlow A: The lack of antidepressant properties and a potent central antiserotonin activity of Org 8282. Pol J Pharmacol Pharm. 1986 Jul-Aug;38(4):377-84. [Article]
- Tohda M, Takasu T, Nomura Y: Effects of antidepressants on serotonin-evoked current in Xenopus oocytes injected with rat brain mRNA. Eur J Pharmacol. 1989 Jul 4;166(1):57-63. [Article]
- Kamimura M, Aoba A: Drug Therapy for Depression in Japan. JMAJ. 2002 Jan;45(1):28-33. [Article]
- Katsuda Y: Monoamine interaction —Effects of long-term treatments with L-tryptophan and setiptiline maleate on rat brain α2- and β-adrenergic receptor— Kawasaki Med J. 1991;17(1-4):37-45. [Article]
- External Links
- KEGG Drug
- D08511
- PubChem Compound
- 5205
- PubChem Substance
- 310265193
- ChemSpider
- 5016
- ChEBI
- 135076
- ChEMBL
- CHEMBL2104895
- ZINC
- ZINC000001482169
- Wikipedia
- Setiptiline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0338 mg/mL ALOGPS logP 3.96 ALOGPS logP 3.98 Chemaxon logS -3.9 ALOGPS pKa (Strongest Basic) 7.44 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 3.24 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 85.53 m3·mol-1 Chemaxon Polarizability 30.49 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Components:
| Name | UniProt ID |
|---|---|
| Alpha-2A adrenergic receptor | P08913 |
| Alpha-2B adrenergic receptor | P18089 |
| Alpha-2C adrenergic receptor | P18825 |
References
- Katsuda Y: Monoamine interaction —Effects of long-term treatments with L-tryptophan and setiptiline maleate on rat brain α2- and β-adrenergic receptor— Kawasaki Med J. 1991;17(1-4):37-45. [Article]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Components:
References
- Tohda M, Takasu T, Nomura Y: Effects of antidepressants on serotonin-evoked current in Xenopus oocytes injected with rat brain mRNA. Eur J Pharmacol. 1989 Jul 4;166(1):57-63. [Article]
Drug created at November 12, 2015 16:07 / Updated at February 03, 2022 06:26